Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1941 STRYKER WAY PORTAGE MI 49002 |
Tel: | N/A |
Website: | https://www.stryker.com |
IR: | See website |
Key People | ||
Kevin A. Lobo Chairman of the Board, President, Chief Executive Officer | Glenn S. Boehnlein Chief Financial Officer, Vice President | Viju S. Menon Group President - Global Quality and Operations |
J. Andrew Pierce Group President - MedSurg and Neurotechnology | Spencer S. Stiles Group President - Orthopaedics and Spine | M. Kathryn Fink Chief Human Resource Officer, Vice President |
William E. Berry Chief Accounting Officer, Vice President | Yin C. Becker Vice President - Chief Corporate Affairs Officer | Robert S. Fletcher Vice President, Chief Legal Officer |
Business Overview |
Stryker Corporation (Stryker) is a medical technology company. It offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. It operates through two segments: MedSurg and Neurotechnology, and Orthopedics and Spine. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products. It also develops neurointerventional devices for the treatment of intracranial aneurysms. It offers Fortress, a modular wall system for hospitals and ambulatory surgery centers. It specializes in soft tissue fixation products and delivering AI-assisted virtual care workflows. |
Financial Overview |
For the six months ended 30 June 2024, Stryker Corp revenues increased 9% to $10.67B. Net income increased 21% to $1.61B. Revenues reflect MedSurg and Neurotechnology segment increase of 10% to $6.12B, Orthopaedics and Spine segment increase of 8% to $4.55B, United States segment increase of 10% to $7.96B, International segment increase of 6% to $2.7B. Net income benefited from MedSurg and Neurotechnology segment income increase of 18% to $1.67B. |
Employees: | 52,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $144,080M as of Jun 30, 2024 |
Annual revenue (TTM): | $21,389M as of Jun 30, 2024 |
EBITDA (TTM): | $5,671M as of Jun 30, 2024 |
Net annual income (TTM): | $3,448M as of Jun 30, 2024 |
Free cash flow (TTM): | $1,624M as of Jun 30, 2024 |
Net Debt Last Fiscal Year: | $10,265M as of Jun 30, 2024 |
Shares outstanding: | 381,100,000 as of Jun 30, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |